Wird geladen...

Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer

Palbociclib was approved by the FDA for use in combination with letrozole for the treatment of postmenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer as initial endocrine-based therapy. In addition, the combination of palbociclib with fulvestrant resulted in superi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Hematol Oncol
1. Verfasser: Lu, Janice
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2015
Schlagworte:
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4534142/
https://ncbi.nlm.nih.gov/pubmed/26264704
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-015-0194-5
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!